Aspire Biopharma converts ~$1.75M debt from PowerUp sponsors into common stock

Aspire Biopharma Holdings, Inc.

Exchanged ~$1.75M debt for common stock at closing price less $0.01/share; holders can submit up to 4 exchange notices by Jan 31, 2026.
Each exchange notice limited to 30% of outstanding balance; shares are freely tradeable without restrictive legends.
Upon a financing over $3M, company may repay debt; holder can elect 25% of outstanding balance from proceeds.
Exchange exempt under Section 3(a)(9) of Securities Act; debt originated from 2024 subscription agreements with PowerUp sponsors.

item 1.01item 3.02item 2.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.